AlloTec
AlloTec is a computational drug discovery company that unlocks allostery for protein-protein interactions, enabling therapeutics for previously undruggable targets in oncology, inflammation, and neurodegenerative diseases. The company integrates machine learning, molecular simulation, and experimental biochemical techniques to elucidate how drug binding induces conformational shifts in proteins. AlloTec is committed to open science, sharing discoveries through peer-reviewed publications and publicly accessible source codes.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
Funding
Founders
Founder details are not available yet.
Product
Problem
Many disease-relevant proteins are considered "undruggable" through conventional orthosteric approaches, which target the primary binding site. The complex regulatory mechanisms of allostery, where effector binding at a distant site alters protein function, remain largely untapped and difficult to characterize, limiting therapeutic development for these challenging targets.
Solution
AlloTec provides a solution that unlocks allostery for protein-protein interactions, enabling the development of therapeutics that modulate these critical biological pathways. The company focuses on the discovery and characterization of allosteric sites and mechanisms on proteins involved in disease, offering a technical platform for drug development. Their approach aims to provide a more sophisticated method to regulate protein function with potentially higher selectivity and fewer side effects compared to traditional orthosteric inhibitors. By targeting allosteric sites, AlloTec's science is designed to enable the creation of novel small molecules and biologics that can precisely tune protein activity.
Target Audience
AlloTec's primary audience includes pharmaceutical and biotechnology companies engaged in drug discovery and development, particularly those seeking novel therapeutic approaches for previously undruggable protein targets in oncology, inflammation, autoimmune, and neurodegenerative diseases.
Features
- Platform focused on allosteric regulation of protein-protein interactions
- Integration of machine learning, molecular simulation, and experimental biochemical techniques
- Pioneering computational assay platform to elucidate how drug binding induces conformational shifts in proteins
- Goal to develop a generalized foundational model of allostery-mediated interactions in oncology, inflammation, and neurodegenerative diseases
- Commitment to open science, including peer-reviewed publications and publicly accessible source codes